Regencell Bioscience Holdings Limited (RGC)
USD 32.64
(-10.03%)
USD 32.64
(-10.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -745.58 Thousand USD | 3.13% |
| 2023 | -769.68 Thousand USD | -27.35% |
| 2022 | -604.39 Thousand USD | -2184.54% |
| 2021 | -26.45 Thousand USD | -178.02% |
| 2020 | -9516.00 USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 3.04 Billion USD | 54.29% |
| 2017 | 1.97 Billion USD | 2.63% |
| 2016 | 1.91 Billion USD | -33.32% |
| 2015 | 2.87 Billion USD | 0.0% |
| 2013 | 2.92 Billion USD | 7.49% |
| 2012 | 2.72 Billion USD | 0.6% |
| 2011 | 2.7 Billion USD | 55.86% |
| 2010 | 1.73 Billion USD | -34.83% |
| 2009 | 2.66 Billion USD | 0.0% |
| 2007 | 2.55 Billion USD | 2.57% |
| 2006 | 2.49 Billion USD | 5.05% |
| 2005 | 2.37 Billion USD | -0.96% |
| 2004 | 2.39 Billion USD | 0.0% |
| 2002 | 2.05 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 100.0% |
| 2023 FY | -769.68 Thousand USD | -27.35% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | -769.68 Thousand USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | -2.34 Billion USD | 0.0% |
| 2022 FY | -604.39 Thousand USD | -2184.54% |
| 2022 Q1 | - USD | 100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 FY | -26.45 Thousand USD | -178.02% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | -3.21 Billion USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | -9516.00 USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 FY | 3.04 Billion USD | 54.29% |
| 2018 Q2 | 537.9 Million USD | 19.24% |
| 2018 Q1 | 451.1 Million USD | -5.05% |
| 2017 Q4 | 475.1 Million USD | -6.35% |
| 2017 Q3 | 507.3 Million USD | -0.12% |
| 2017 Q2 | 507.9 Million USD | 0.65% |
| 2017 Q1 | 504.6 Million USD | 5.79% |
| 2017 FY | 1.97 Billion USD | 2.63% |
| 2016 Q4 | 477 Million USD | -0.79% |
| 2016 FY | 1.91 Billion USD | -33.32% |
| 2016 Q3 | 480.8 Million USD | -7.82% |
| 2016 Q2 | 521.6 Million USD | 15.02% |
| 2016 Q1 | 453.5 Million USD | -11.72% |
| 2015 FY | 2.87 Billion USD | 0.0% |
| 2015 Q4 | 513.7 Million USD | 19.19% |
| 2015 Q2 | 768.1 Million USD | 15.02% |
| 2015 Q3 | 431 Million USD | -43.89% |
| 2015 Q1 | 667.8 Million USD | -10.04% |
| 2014 Q4 | 742.3 Million USD | 5.91% |
| 2014 Q2 | 713.9 Million USD | -8.84% |
| 2014 Q1 | 783.1 Million USD | -3.36% |
| 2014 Q3 | 700.9 Million USD | -1.82% |
| 2013 Q4 | 810.3 Million USD | 30.74% |
| 2013 FY | 2.92 Billion USD | 7.49% |
| 2013 Q2 | 697.1 Million USD | 4.53% |
| 2013 Q1 | 666.9 Million USD | -4.36% |
| 2013 Q3 | 619.8 Million USD | -11.09% |
| 2012 Q4 | 697.3 Million USD | 5.35% |
| 2012 FY | 2.72 Billion USD | 0.6% |
| 2012 Q1 | 716.6 Million USD | 58.22% |
| 2012 Q2 | 591.9 Million USD | -17.4% |
| 2012 Q3 | 661.9 Million USD | 11.83% |
| 2011 Q3 | 354.2 Million USD | -44.57% |
| 2011 FY | 2.7 Billion USD | 55.86% |
| 2011 Q1 | 415.8 Million USD | -69.25% |
| 2011 Q2 | 639 Million USD | 53.68% |
| 2011 Q4 | 452.9 Million USD | 27.87% |
| 2010 Q1 | 647 Million USD | -14.64% |
| 2010 FY | 1.73 Billion USD | -34.83% |
| 2010 Q4 | 1.35 Billion USD | 95.12% |
| 2010 Q3 | 693 Million USD | 50.98% |
| 2010 Q2 | 459 Million USD | -29.06% |
| 2009 Q2 | 683 Million USD | -6.18% |
| 2009 Q3 | 641 Million USD | -6.15% |
| 2009 Q1 | 728 Million USD | 12.0% |
| 2009 FY | 2.66 Billion USD | 0.0% |
| 2009 Q4 | 758 Million USD | 18.25% |
| 2008 Q1 | 723 Million USD | 10.21% |
| 2008 Q4 | 650 Million USD | 7.62% |
| 2008 Q3 | 604 Million USD | 4.32% |
| 2008 Q2 | 579 Million USD | -19.92% |
| 2007 FY | 2.55 Billion USD | 2.57% |
| 2007 Q1 | 648 Million USD | -1.22% |
| 2007 Q2 | 629 Million USD | -2.93% |
| 2007 Q3 | 600 Million USD | -4.61% |
| 2007 Q4 | 656 Million USD | 9.33% |
| 2006 Q2 | 643 Million USD | 6.46% |
| 2006 Q3 | 561 Million USD | -12.75% |
| 2006 FY | 2.49 Billion USD | 5.05% |
| 2006 Q4 | 656 Million USD | 16.93% |
| 2006 Q1 | 604 Million USD | 178.21% |
| 2005 Q4 | 217.1 Million USD | 11.96% |
| 2005 FY | 2.37 Billion USD | -0.96% |
| 2005 Q1 | 206.7 Million USD | 62.76% |
| 2005 Q2 | 1.78 Billion USD | 764.05% |
| 2005 Q3 | 193.9 Million USD | -89.14% |
| 2004 Q3 | 520 Million USD | -70.97% |
| 2004 Q1 | 606 Million USD | 426.96% |
| 2004 Q2 | 1.79 Billion USD | 195.54% |
| 2004 Q4 | 127 Million USD | -75.58% |
| 2004 FY | 2.39 Billion USD | 0.0% |
| 2003 Q4 | 115 Million USD | -77.41% |
| 2003 Q2 | 1.5 Billion USD | 174.5% |
| 2003 Q3 | 509 Million USD | -66.22% |
| 2003 Q1 | 549 Million USD | -5.67% |
| 2002 FY | 2.05 Billion USD | 0.0% |
| 2002 Q4 | 582 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 100.229% |
| Embecta Corp. | 749.9 Million USD | 100.099% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 100.244% |
| Dynavax Technologies Corporation | 182.11 Million USD | 100.409% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 101.02% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 100.152% |
| PainReform Ltd. | -15 Thousand USD | -4870.587% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 102.506% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 108.941% |
| SCYNEXIS, Inc. | 124.51 Million USD | 100.599% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | 234.59% |
| Cosmos Health Inc. | 4.34 Million USD | 117.142% |
| Journey Medical Corporation | 52.52 Million USD | 101.42% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 108.941% |
| Safety Shot Inc | -74.45 Thousand USD | -901.367% |
| Alpha Teknova, Inc. | 10.29 Million USD | 107.242% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 100.173% |
| Bright Green Corporation | -237.01 Thousand USD | -214.573% |
| Procaps Group, S.A. | 239.56 Million USD | 100.311% |
| Theratechnologies Inc. | 62.12 Million USD | 101.2% |
| Harrow Health, Inc. | 90.55 Million USD | 100.823% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 115.713% |
| Biofrontera Inc. | 16.62 Million USD | 104.484% |
| DURECT Corporation | 6.83 Million USD | 110.915% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.142% |
| Cronos Group Inc. | 6.99 Million USD | 110.665% |
| OptiNose, Inc. | 62.35 Million USD | 101.196% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 100.169% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -146.069% |
| RedHill Biopharma Ltd. | 3.05 Million USD | 124.412% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 100.241% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | 113.821% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 102.227% |
| Radius Health, Inc. | 307.71 Million USD | 100.242% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 107.398% |
| ProPhase Labs, Inc. | 16.23 Million USD | 104.591% |
| Phibro Animal Health Corporation | 312.48 Million USD | 100.239% |
| Procaps Group S.A. | 239.56 Million USD | 100.311% |
| Alvotech | -69.42 Million USD | 98.926% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 157.265% |
| Viatris Inc. | 6.43 Billion USD | 100.012% |
| Rockwell Medical, Inc. | 8.7 Million USD | 108.566% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 101.366% |
| SIGA Technologies, Inc. | 122.09 Million USD | 100.611% |
| Tilray Brands, Inc. | 223.35 Million USD | 100.334% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 101.782% |
| Shineco, Inc. | 882.16 Thousand USD | 184.518% |
| PetIQ, Inc. | 252.74 Million USD | 100.295% |
| Incannex Healthcare Limited | 12 Thousand USD | 6313.233% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.04% |
| Alimera Sciences, Inc. | 61.17 Million USD | 101.219% |
| Silver Spike Investment Corp. | 8.1 Million USD | 109.202% |
| Assertio Holdings, Inc. | 125.04 Million USD | 100.596% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | -10846.821% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | 117.79% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 111.373% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 69.065% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 102.75% |
| Hempacco Co., Inc. | -1.21 Million USD | 38.677% |
| Talphera, Inc. | -4.89 Million USD | 84.768% |
| Alvotech | -69.42 Million USD | 98.926% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 100.336% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 100.105% |
| Currenc Group, Inc. | 17.35 Million USD | 104.296% |
| Kamada Ltd. | 52.59 Million USD | 101.418% |
| Indivior PLC | 907 Million USD | 100.082% |
| Evoke Pharma, Inc. | 4.97 Million USD | 114.975% |
| Flora Growth Corp. | 17.73 Million USD | 104.203% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 69.065% |
| Evolus, Inc. | 140.52 Million USD | 100.531% |
| HUTCHMED (China) Limited | 453.55 Million USD | 100.164% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 100.217% |
| Akanda Corp. | 111.44 Thousand USD | 768.995% |